Lenalidomide Accord

Lenalidomide, the active ingredient in Lenalidomide Accord, is an immunomodulatory drug presented as an oral formulation for oral use. It is employed in the treatment of certain hematologic malignancies, notably multiple myeloma and myelodysplastic syndromes with del(5q), and is indicated for adult patients who have received prior therapy.

GNH USA supplies Lenalidomide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, providing reliable sourcing, regulatory documentation and logistics support for global clinical and commercial use.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

Multiple Myeloma: improves progression‑free survival and overall response when combined with dexamethasone or other agents. Myelodysplastic Syndromes (del(5q)): reduces transfusion dependence and can induce cytogenetic remission.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Fatigue - Nausea - Diarrhea - Constipation - Rash - Neutropenia

Serious or Rare Side Effects: - Thromboembolic events (deep‑vein thrombosis, pulmonary embolism) - Severe neutropenia or leukopenia - Life‑threatening infections - Secondary primary malignancies - Elevated liver enzymes or hepatic dysfunction - Embryofetal toxicity

Use requires careful clinical monitoring and patient counseling.

Pregnancy risk: drug is teratogenic; avoid use in pregnant women and ensure effective contraception. Renal impairment: dose adjustment may be required based on renal function. Hematologic monitoring: perform regular complete blood counts to detect cytopenias. Thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. Drug interactions: review concomitant medications for potential interactions. Store at ambient temperature: keep below 25 °C, in original container, protect from moisture and light.

Lenalidomide may interact with several co‑administered medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure. - Live vaccines: concurrent use may increase risk of infection. - Anticoagulants (e.g., warfarin): may enhance bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide efficacy. - Nephrotoxic agents (e.g., NSAIDs, aminoglycosides): may worsen renal function. - Immunosuppressants (e.g., cyclosporine): may increase infection risk.